MyFinsight
Home
Blog
About
Proceeds from sales and
maturities of marketable...
$19,250K
(-64.99%↓ Y/Y)
Proceeds from exercise of
employee stock options...
$114K
Net cash (used in)
provided by investing...
$10,263K
(-57.53%↓ Y/Y)
Net cash provided by
(used in) financing...
$91K
(132.04%↑ Y/Y)
Canceled cashflow
$8,987K
Canceled cashflow
$23K
Net (decrease)
increase in cash and cash...
-$9,493K
(-1240.99%↓ Y/Y)
Canceled cashflow
$10,354K
Stock-based compensation
expense
$2,672K
(-59.50%↓ Y/Y)
Accounts payable
$842K
(-79.50%↓ Y/Y)
Revaluation of contingent
consideration
$300K
(-83.33%↓ Y/Y)
Depreciation and
amortization
$107K
(-55.79%↓ Y/Y)
Purchases of marketable
securities
$8,929K
(-70.16%↓ Y/Y)
Purchases of property and
equipment
$58K
(-9.38%↓ Y/Y)
Payments of employee
withholding taxes related to...
$23K
(-91.90%↓ Y/Y)
Net cash used in
operating activities
-$19,847K
(13.90%↑ Y/Y)
Canceled cashflow
$3,921K
Net loss
-$21,505K
(29.52%↑ Y/Y)
Accounts receivable,
prepaid expenses and...
$1,219K
Deferred income
-$972K
(45.85%↑ Y/Y)
Accrued expenses and
other liabilities
-$72K
(99.32%↑ Y/Y)
Back
Back
Cash Flow
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)
source: myfinsight.com